Literature DB >> 24531827

[Medicinal rate control in atrial fibrillation].

Michael Näbauer1.   

Abstract

Atrial fibrillation is the most common form of persistent arrhythmia. Atrial fibrillation frequently causes rapid ventricular response with severe clinical symptoms requiring acute control of the ventricular rate. This leads to hemodynamic stabilization and improvement of symptoms. The long-term treatment target is to minimize patient symptoms and prevention of complications. As a rhythm control strategy does not provide a survival benefit compared to a rate control strategy, decisions on the best long-term treatment have to be individualized. Important factors affecting this decision are age of the patient, chances to re-establish and maintain sinus rhythm, tolerance of antiarrhythmic medication and accompanying diseases of the heart. For younger patients a rhythm control strategy will usually be the preferred option. For rate control beta blockers are considered first line therapy, alternative drugs include calcium antagonists and digoxin. Occasionally, amiodarone may also be used for rate control. If pharmacological rate management fails ablation of the atrioventricular (AV) node may be an option to control the ventricular rate.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24531827     DOI: 10.1007/s00399-014-0299-5

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  20 in total

1.  Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation.

Authors:  Raluca Ionescu-Ittu; Michal Abrahamowicz; Cynthia A Jackevicius; Vidal Essebag; Mark J Eisenberg; Willy Wynant; Hugues Richard; Louise Pilote
Journal:  Arch Intern Med       Date:  2012-07-09

2.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.

Authors:  Isabelle C Van Gelder; Vincent E Hagens; Hans A Bosker; J Herre Kingma; Otto Kamp; Tsjerk Kingma; Salah A Said; Julius I Darmanata; Alphons J M Timmermans; Jan G P Tijssen; Harry J G M Crijns
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

3.  Is there a role for maintaining sinus rhythm in patients with atrial fibrillation?

Authors:  Peter Zimetbaum; Mark E Josephson
Journal:  Ann Intern Med       Date:  2004-11-02       Impact factor: 25.391

4.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.

Authors:  Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; Jean-Yves Le Heuzey; G Neal Kay; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; Samuel Wann; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffery L Anderson; Elliott M Antman; Jonathan L Halperin; Sharon Ann Hunt; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Silvia G Priori; Jean-Jacques Blanc; Andrzej Budaj; A John Camm; Veronica Dean; Jaap W Deckers; Catherine Despres; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; Joao Morais; Ady Osterspey; Juan Luis Tamargo; José Luis Zamorano
Journal:  Europace       Date:  2006-09       Impact factor: 5.214

5.  Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial.

Authors:  Paulus Kirchhof; Günter Breithardt; A John Camm; Harry J Crijns; Karl-Heinz Kuck; Panos Vardas; Karl Wegscheider
Journal:  Am Heart J       Date:  2013-07-30       Impact factor: 4.749

6.  Heart rate-reducing effects of bisoprolol in Japanese patients with chronic atrial fibrillation: results of the MAIN-AF study.

Authors:  Takeshi Yamashita; Hiroshi Inoue
Journal:  J Cardiol       Date:  2013-04-20       Impact factor: 3.159

7.  Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens.

Authors:  R Farshi; D Kistner; J S Sarma; J A Longmate; B N Singh
Journal:  J Am Coll Cardiol       Date:  1999-02       Impact factor: 24.094

8.  Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.

Authors:  Scott D Corley; Andrew E Epstein; John P DiMarco; Michael J Domanski; Nancy Geller; H Leon Greene; Richard A Josephson; Joyce C Kellen; Richard C Klein; Andrew D Krahn; Mary Mickel; L Brent Mitchell; Joy Dalquist Nelson; Yves Rosenberg; Eleanor Schron; Lynn Shemanski; Albert L Waldo; D George Wyse
Journal:  Circulation       Date:  2004-03-08       Impact factor: 29.690

9.  Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.

Authors:  Jonathan S Steinberg; Ara Sadaniantz; Jack Kron; Andrew Krahn; D Marty Denny; James Daubert; W Barton Campbell; Edward Havranek; Katherine Murray; Brian Olshansky; Gearoid O'Neill; Magdi Sami; Stanley Schmidt; Randle Storm; Miguel Zabalgoitia; John Miller; Mary Chandler; Elaine M Nasco; H Leon Greene
Journal:  Circulation       Date:  2004-03-29       Impact factor: 29.690

10.  Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation.

Authors:  Sara R Ulimoen; Steve Enger; Jonas Carlson; Pyotr G Platonov; Are H Pripp; Michael Abdelnoor; Harald Arnesen; Knut Gjesdal; Arnljot Tveit
Journal:  Am J Cardiol       Date:  2012-10-27       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.